{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:55:45Z","timestamp":1790913345920,"version":"4.1.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the available evidence regarding the use of linezolid for the treatment of Nocardia spp. infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Data were identified through a search of MEDLINE (1966-May 2007), American Search Premier (1975-May 2007), International Pharmaceutical Abstracts (1960-2007), Science Citation Index Expanded (1996-2007), and Cochrane Databases (publications archived until May 2007) using the terms linezolid and Nocardia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Prospective and retrospective studies, case reports, case series, and in vitro studies were eligible for inclusion if they used linezolid for nocardiosis regardless of site of infection and outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>We identified 11 published cases of linezolid use for Nocardia spp. infections. The predominant species isolated were N. asteroides (n=4; 36%) and N. farcinica (n= 3; 27%). Nocardiosis with central nervous system involvement (n= 7; 64%) or disseminated disease (n= 4; 36%) were most common. The main reason for discontinuation of previous antimicrobials was most often related to adverse effects (n= 5; 45%), followed by clinical failure (n = 3; 27%). Linezolid was associated with cure or improvement in all cases (n =11; 100%). However, the majority of patients developed serious complications that may have led to premature discontinuation of therapy with linezolid, including myelosuppression (n = 5; 45%) or possible\/confirmed peripheral neuropathy (n = 2; 18%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The limited published data suggest that linezolid appears to be an effective alternative to trimethoprim\/sulfamethoxazole for the treatment of nocardiosis. Unfortunately, the high cost and potentially serious long-term toxicities of linezolid appear to limit its use and relegate it to salvage therapy alone or in combination with other antimicrobials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1k196","type":"journal-article","created":{"date-parts":[[2007,9,4]],"date-time":"2007-09-04T21:11:11Z","timestamp":1188940271000},"page":"1694-1699","source":"Crossref","is-referenced-by-count":58,"title":["LInezolid for the Treatment of Nocardia spp. Infections"],"prefix":"10.1177","volume":"41","author":[{"given":"Tomasz Z","family":"Jodlowski","sequence":"first","affiliation":[{"name":"St. John's University, Queens, NY; Clinical Coordinator, Jacobi Medical Center, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Melnychuk","sequence":"additional","affiliation":[{"name":"Baptist Medical Center Beaches, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Conry","sequence":"additional","affiliation":[{"name":"St. John's University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"bibr1-aph.1K196","first-page":"2916","volume-title":"Principles and practice of infectious diseases","author":"Sorrell TC","year":"2005","edition":"6"},{"key":"bibr2-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-3019(00)00242-1"},{"key":"bibr3-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.6.891"},{"key":"bibr4-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1086\/345907"},{"key":"bibr5-aph.1K196","unstructured":"Package insert. Zyvox (linezolid). New York: Pharmacia and Upjohn, Division of Pfizer, July 2006."},{"key":"bibr6-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1295-1297.2001"},{"key":"bibr7-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01460.x"},{"key":"bibr8-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3629-3630.2001"},{"key":"bibr9-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2002.1122"},{"key":"bibr10-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1097\/01.RHU.0000049715.31325.72"},{"key":"bibr11-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01001.x"},{"key":"bibr12-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-005-1978-6"},{"key":"bibr13-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0262-x"},{"key":"bibr14-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.936-937.2002"},{"key":"bibr15-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H307"},{"key":"bibr16-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.12.1784"},{"key":"bibr17-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1086\/504809"},{"key":"bibr18-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1086\/503839"},{"key":"bibr19-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E523"},{"key":"bibr20-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1086\/379012"},{"key":"bibr21-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.11.047"},{"key":"bibr22-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01109-0"},{"key":"bibr23-aph.1K196","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.927"},{"key":"bibr24-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh405"},{"key":"bibr25-aph.1K196","doi-asserted-by":"publisher","DOI":"10.1086\/508280"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1K196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:27Z","timestamp":1777374507000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1K196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1345\/aph.1K196"],"URL":"https:\/\/doi.org\/10.1345\/aph.1k196","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}